1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,550 | 10,200 | 22.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Di | Pharming Group N.V.: Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026 | 155 | GlobeNewswire (Europe) | Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report... ► Artikel lesen | |
| Fr | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | 431 | EQS Group (EN) | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
18.09.2026 / 11:30 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| Do | Pharming Group (PHAR) Expands Joenja's Pediatric Label. Can Growth Offset RUCONEST Weakness? | 4 | Insider Monkey | ||
| 11.09. | Pharming Gets FDA Approval For Joenja In Children With APDS | 2 | RTTNews | ||
| 11.09. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.09. | Pharming Group N.V.: FDA approves Pharming's Joenja as first treatment for children with APDS in the U.S. | 405 | GlobeNewswire (Europe) | FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are... ► Artikel lesen | |
| 11.09. | Pharming wins approval of Joenja for younger age group | 1 | Seeking Alpha | ||
| 09.09. | Pharming Group N.V.: Pharming Group to participate in September investor conferences | 386 | GlobeNewswire (Europe) | Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences... ► Artikel lesen | |
| 13.08. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.08. | Pharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older | 424 | GlobeNewswire (Europe) | Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and... ► Artikel lesen | |
| 04.08. | Pharming Group N.V.: Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference | 503 | GlobeNewswire (Europe) | Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston... ► Artikel lesen | |
| 30.07. | Oppenheimer cuts Pharming Group stock price target on lowered guidance | 9 | Investing.com | ||
| 30.07. | Oppenheimer senkt Kursziel für Pharming Group nach Prognosekorrektur | 9 | Investing.com Deutsch | ||
| 30.07. | Pharming Q2 2026 slides: Joenja growth offsets RUCONEST pressure | 1 | Investing.com | ||
| 30.07. | Pharming GAAP EPS of $0.00 misses by $0.06, revenue of $90.2M misses by $9.32M | 4 | Seeking Alpha | ||
| 30.07. | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 30.07. | Pharming Group senkt Umsatzprognose für 2026 wegen schwacher Absatzzahlen | 15 | Investing.com Deutsch | ||
| 30.07. | Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use | 1.259 | GlobeNewswire (Europe) | For investor audiences and media only
Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST revenue was US$72.3 million, a 10% decrease... ► Artikel lesen | |
| 22.07. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | 481 | EQS Group (EN) | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
22.07.2026 / 16:49 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,806 | +0,43 % | Novo Nordisk, BioNxt Solutions, Evotec - wenn aus Spritzen Tabletten werden, klingelt die Kasse | Die tägliche Spritze hat ihre besten Tage hinter sich. Biologika als Tablette zu schlucken galt lange als Utopie, seit diesem Jahr wird daraus ein Milliardengeschäft. Am 17. September 2026 gab Novo... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,74 % | Qiagen sorgt für Gesprächsstoff, Rheinmetall bleibt unter Druck, Nvidia zeigt sich freundlicher und Siemens Energy profitiert von neuer Zuversicht im KI-Segment | Die Zinserhöhung der Fed sowie die Aussicht auf weitere Zinsschritte in der nahen Zukunft scheinen die Märkte erstaunlich schnell verdaut zu haben. Statt weiterer Kursstürze gab es am Donnerstag dann... ► Artikel lesen | |
| VALNEVA | 2,844 | +1,57 % | RALLYE bei Valneva: +37,7% Potenzial - Jetzt einsteigen? | ||
| STRYKER | 240,80 | +0,21 % | TD Cowen cuts Stryker stock price target to $298 on margin concerns | ||
| ILLUMINA | 216,50 | +0,14 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,390 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,901 | -1,31 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,200 | +1,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,090 | +0,46 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,900 | -1,65 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| IDEXX LABORATORIES | 457,00 | +0,31 % | IDEXX Laboratories, Inc.: IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection | Expanded testing menu now detects more intestinal parasites during routine visits
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,291 | +0,19 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,551 | +1,90 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH | 207,20 | +0,19 % | BARCLAYS stuft Sartorius Stedim Biotech auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Sartorius Stedim von 210 auf 240 Euro angehoben und die Einstufung auf "Overweight" belassen. Analyst James Gordon... ► Artikel lesen | |
| CG ONCOLOGY | 77,74 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen |
PHARMING GROUP NV ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,250 Euro und damit +4,52 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.